0001209191-19-003996.txt : 20190116
0001209191-19-003996.hdr.sgml : 20190116
20190116190937
ACCESSION NUMBER: 0001209191-19-003996
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190115
FILED AS OF DATE: 20190116
DATE AS OF CHANGE: 20190116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Londei Marco
CENTRAL INDEX KEY: 0001654500
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 19529883
MAIL ADDRESS:
STREET 1: C/O ANAPTYSBIO, INC.
STREET 2: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-15
0
0001370053
ANAPTYSBIO INC
ANAB
0001654500
Londei Marco
C/O ANAPTYSBIO, INC.
10421 PACIFIC CENTER COURT, SUITE 200
SAN DIEGO
CA
92121
0
1
0
0
Chief Medical Officer
Common Stock
2018-12-26
5
G
0
E
122500
0.00
D
22377
D
Common Stock
2019-01-15
4
M
0
19075
6.93
A
41452
D
Common Stock
2019-01-15
4
S
0
4181
69.2864
D
37271
D
Common Stock
2019-01-15
4
S
0
14894
70.0413
D
22377
D
Employee Stock Option (Right to Buy)
6.93
2019-01-15
4
M
0
19075
0.00
D
2025-08-13
Common Stock
19075
51148
D
Represents the number of shares of Issuer's common stock that were donated as a charitable contribution. The reporting person does not exercise voting or dispositive powers, directly or indirectly, over the donated shares following this transfer.
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.63 to $69.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.63 to $70.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
In addition to the remaining options to purchase 51,148 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 148,060 shares of common stock, which options vest according to their terms, and (ii) 22,377 shares of common stock held directly.
/s/Eric Loumeau, attorney-in-fact
2019-01-16